He Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
He Zhou has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Jie Liang
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China
4 shared publications Song Su
3 shared publicationsJiayao Wang
2 shared publications- Jie Liang
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China; Department of Digestive Diseases, Xijing Hospital of Fourth Military Medical University, Xi'an, China
2 shared publications Nan Wu
Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education. School of Medicine, Northwest University, Xi’an, China
2 shared publications- Tong Wu
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China
2 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Elsevier in SSRN Electronic Journal
Clinical and Histological Evidence Against a Role for Helicobacter pylori in Intestinal Subtype Ampullary Carcinoma (ISAC)
Background: Intestinal subtype ampullary carcinoma (ISAC) carries a poor prognosis once it invades the pancreaticobiliary ducts. Identifying risk factors may facilitate risk stratification and early detection before invasion. Several mechanistic considerations suggest a plausible link between Helicobacter pylori (H. pylori) and ISAC, but direct evidence is lacking. We aim to assess whether H. pylori infection is associated with ISAC risk and to identify other risk and protective factors for ISAC in individuals with documented H. pylori testing.Methods: In this case–control study, consecutive esophagogastroduodenoscopy (EGD) records from 2014 to 2024 were screened. ISAC cases were diagnosed according to NCCN guidelines. Controls were individuals whose duodenal papilla biopsies showed normal mucosa or inflammation only, with no ampullary abnormalities detected during follow‑up. All included patients had documented H. pylori testing. Multivariable logistic regression was used to estimate adjusted odds ratios (ORs) with 95% CIs. To ensure robustness, two complementary exposure definitions, namely ever infection and at‑diagnosis positivity, were employed, and a series of additional analyses were performed, including restricted cubic spline modeling, sensitivity analyses, multicollinearity diagnostics, subgroup analyses, and E‑value analysis. To further validate the clinical findings, histopathological triple staining (hematoxylin‑eosin, immunohistochemistry, and Warthin‑Starry) was conducted on ISAC and paired gastric mucosal tissues.Findings: A total of 347,311 EGD was screened and 325 participants (106 ISAC cases and 219 controls) were analyzed according to inclusion and exclusion criteria. Neither ever H. pylori infection (adjusted OR, 1.26; 95% CI, 0.69–2.30) nor at‑diagnosis H. pylori positivity (adjusted OR, 1.36; 95% CI, 0.75–2.46) was associated with ISAC risk. All robustness analyses consistently confirmed no association between H. pylori and ISAC. Histopathological triple staining corroborated the clinical finding of no association: H. pylori was present in paired gastric mucosa but absent from all ISAC tissues. Beyond this core finding, age, female sex, and regular alcohol intake were identified as independent risk factors, whereas H. pylori eradication therapy and long‑term statin use were independent protective factors.Interpretation: Convergent clinical and histopathological evidence did not support an association between H. pylori and ISAC. Together with the identified risk and protective factors, these findings advance the understanding of ISAC, refine risk stratification, and redirect etiological research.
- 16 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessClinical and Histological Evidence Against a Role for Helicobacter pylori in Intestinal Subtype Ampullary Carcinoma (ISAC)
Background: Intestinal subtype ampullary carcinoma (ISAC) carries a poor prognosis once it invades the pancreaticobiliary ducts. Identifying risk factors may facilitate risk stratification and early detection before invasion. Several mechanistic considerations suggest a plausible link between Helicobacter pylori (H. pylori) and ISAC, but direct evidence is lacking. We aim to assess whether H. pylori infection is associated with ISAC risk and to identify other risk and protective factors for ISAC in individuals with documented H. pylori testing.Methods: In this case–control study, consecutive esophagogastroduodenoscopy (EGD) records from 2014 to 2024 were screened. ISAC cases were diagnosed according to NCCN guidelines. Controls were individuals whose duodenal papilla biopsies showed normal mucosa or inflammation only, with no ampullary abnormalities detected during follow‑up. All included patients had documented H. pylori testing. Multivariable logistic regression was used to estimate adjusted odds ratios (ORs) with 95% CIs. To ensure robustness, two complementary exposure definitions, namely ever infection and at‑diagnosis positivity, were employed, and a series of additional analyses were performed, including restricted cubic spline modeling, sensitivity analyses, multicollinearity diagnostics, subgroup analyses, and E‑value analysis. To further validate the clinical findings, histopathological triple staining (hematoxylin‑eosin, immunohistochemistry, and Warthin‑Starry) was conducted on ISAC and paired gastric mucosal tissues.Findings: A total of 347,311 EGD was screened and 325 participants (106 ISAC cases and 219 controls) were analyzed according to inclusion and exclusion criteria. Neither ever H. pylori infection (adjusted OR, 1.26; 95% CI, 0.69–2.30) nor at‑diagnosis H. pylori positivity (adjusted OR, 1.36; 95% CI, 0.75–2.46) was associated with ISAC risk. All robustness analyses consistently confirmed no association between H. pylori and ISAC. Histopathological triple staining corroborated the clinical finding of no association: H. pylori was present in paired gastric mucosa but absent from all ISAC tissues. Beyond this core finding, age, female sex, and regular alcohol intake were identified as independent risk factors, whereas H. pylori eradication therapy and long‑term statin use were independent protective factors.Interpretation: Convergent clinical and histopathological evidence did not support an association between H. pylori and ISAC. Together with the identified risk and protective factors, these findings advance the understanding of ISAC, refine risk stratification, and redirect etiological research.
- Open Access
- 10 March 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 677
Causal Relationships Between Iron Deficiency Anemia, Gut Microbiota, and Metabolites: Insights from Mendelian Randomization and In Vivo Data
Background: Iron deficiency anemia (IDA) is a common type of anemia in children and pregnant women. The effects of iron deficiency on gut microbiota and metabolic profiles are not fully understood. Methods: Mendelian randomization (MR) analysis was conducted to explore associations among IDA, gut microbiota, and metabolites. MR analysis was conducted using computational methods, utilizing human genetic data. Data were obtained from genome-wide association studies (GWAS), with inverse-variance-weighted (IVW) as the primary method. Animal models evaluated the effects of IDA on gut microbiota and metabolic profiles. Results: IVW analysis revealed significant associations between gut microbial taxa and IDA. The genus Desulfovibrio was protective (OR = 0.85, 95% CI: 0.77–0.93, p = 0.001), while Actinomyces (OR = 1.12, 95% CI: 1.01–1.23, p = 0.025) and family XIII (OR = 1.16, 95% CI: 1.01–1.32, p = 0.035) increased IDA risk. Glycine was protective (OR = 0.95, 95% CI: 0.91–0.99, p = 0.011), whereas medium low density lipoprotein (LDL) phospholipids increased risk (OR = 1.07, 95% CI: 1.00–1.15, p = 0.040). Animal models confirmed reduced Desulfovibrio, increased Actinomyces, and altered metabolites, including amino acids and phospholipids. Conclusions: IDA significantly impacts gut microbiota and metabolic profiles, offering insights for therapeutic strategies targeting microbiota and metabolism.
- 10 March 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 677
Open AccessCausal Relationships Between Iron Deficiency Anemia, Gut Microbiota, and Metabolites: Insights from Mendelian Randomization and In Vivo Data
Background: Iron deficiency anemia (IDA) is a common type of anemia in children and pregnant women. The effects of iron deficiency on gut microbiota and metabolic profiles are not fully understood. Methods: Mendelian randomization (MR) analysis was conducted to explore associations among IDA, gut microbiota, and metabolites. MR analysis was conducted using computational methods, utilizing human genetic data. Data were obtained from genome-wide association studies (GWAS), with inverse-variance-weighted (IVW) as the primary method. Animal models evaluated the effects of IDA on gut microbiota and metabolic profiles. Results: IVW analysis revealed significant associations between gut microbial taxa and IDA. The genus Desulfovibrio was protective (OR = 0.85, 95% CI: 0.77–0.93, p = 0.001), while Actinomyces (OR = 1.12, 95% CI: 1.01–1.23, p = 0.025) and family XIII (OR = 1.16, 95% CI: 1.01–1.32, p = 0.035) increased IDA risk. Glycine was protective (OR = 0.95, 95% CI: 0.91–0.99, p = 0.011), whereas medium low density lipoprotein (LDL) phospholipids increased risk (OR = 1.07, 95% CI: 1.00–1.15, p = 0.040). Animal models confirmed reduced Desulfovibrio, increased Actinomyces, and altered metabolites, including amino acids and phospholipids. Conclusions: IDA significantly impacts gut microbiota and metabolic profiles, offering insights for therapeutic strategies targeting microbiota and metabolism.
- Open Access
- 27 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1894
Systematic Review and Meta-Analysis of Observational Studies on the Effectiveness and Safety of Ustekinumab among Patients with Inflammatory Bowel Disease in Eastern and Western Countries
Background: Ustekinumab (UST) is an IL12/23 inhibitor utilized for altering inflammatory responses in inflammatory bowel disease (IBD). Clinical trials and case reports suggested that the effectiveness and safety of UST may differ among IBD patients in Eastern and Western countries. However, related data have not been systematically reviewed and analyzed. Methods: This systematic review and meta-analysis of the safety and effectiveness of UST in IBD included relevant literature from the Medline and Embase databases. The main outcomes were clinical response, clinical remission, endoscopic response, endoscopic remission, and adverse events in IBD. Results: We analyzed 49 real-world studies, most of which included patients with biological failure (89.1% CD and 97.1% UC). In UC patients, clinical remission rates were 34% at 12 weeks, 40% at 24 weeks, and 37% at 1 year. In CD patients, clinical remission rates were 46% at 12 weeks, 51% at 24 weeks, and 47% at 1 year. Clinical remission rates of CD patients were 40% at 12 weeks and 44% at 24 weeks in Western countries, versus 63% and 72% in Eastern countries, respectively. Conclusion: UST is an effective drug for IBD with a promising safety profile. Although no RCTs have been performed in Eastern countries, the effectiveness of UST on CD patients is not inferior to that in Western countries based on the existing data.
- 27 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1894
Open AccessSystematic Review and Meta-Analysis of Observational Studies on the Effectiveness and Safety of Ustekinumab among Patients with Inflammatory Bowel Disease in Eastern and Western Countries
Background: Ustekinumab (UST) is an IL12/23 inhibitor utilized for altering inflammatory responses in inflammatory bowel disease (IBD). Clinical trials and case reports suggested that the effectiveness and safety of UST may differ among IBD patients in Eastern and Western countries. However, related data have not been systematically reviewed and analyzed. Methods: This systematic review and meta-analysis of the safety and effectiveness of UST in IBD included relevant literature from the Medline and Embase databases. The main outcomes were clinical response, clinical remission, endoscopic response, endoscopic remission, and adverse events in IBD. Results: We analyzed 49 real-world studies, most of which included patients with biological failure (89.1% CD and 97.1% UC). In UC patients, clinical remission rates were 34% at 12 weeks, 40% at 24 weeks, and 37% at 1 year. In CD patients, clinical remission rates were 46% at 12 weeks, 51% at 24 weeks, and 47% at 1 year. Clinical remission rates of CD patients were 40% at 12 weeks and 44% at 24 weeks in Western countries, versus 63% and 72% in Eastern countries, respectively. Conclusion: UST is an effective drug for IBD with a promising safety profile. Although no RCTs have been performed in Eastern countries, the effectiveness of UST on CD patients is not inferior to that in Western countries based on the existing data.
- Open Access
- 8 February 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1135930
Vitamin D3 alleviates inflammation in ulcerative colitis by activating the VDR-NLRP6 signaling pathway
Inflammation is a key factor in the development of ulcerative colitis (UC). 1,25-dihydroxyvitamin D3 (1,25(OH)2D3, VD3), as the major active ingredient of vitamin D and an anti-inflammatory activator, is closely related to the initiation and development of UC, but its regulatory mechanism remains unclear. In this study, we carried out histological and physiological analyses in UC patients and UC mice. RNA sequencing (RNA-seq), assays for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq), chromatin immunoprecipitation (ChIP) assays and protein and mRNA expression were performed to analyze and identify the potential molecular mechanism in UC mice and lipopolysaccharide (LPS)-induced mouse intestinal epithelial cells (MIECs). Moreover, we established nucleotide-binding oligomerization domain (NOD)-like receptor protein nlrp6-/- mice and siRNA-NLRP6 MIECs to further characterize the role of NLRP6 in anti-inflammation of VD3. Our study revealed that VD3 abolished NOD-like receptor protein 6 (NLRP6) inflammasome activation, suppressing NLRP6, apoptosis-associated speck-like protein (ASC) and Caspase-1 levels via the vitamin D receptor (VDR). ChIP and ATAC-seq showed that VDR transcriptionally repressed NLRP6 by binding to vitamin D response elements (VDREs) in the promoter of NLRP6, impairing UC development. Importantly, VD3 had both preventive and therapeutic effects on the UC mouse model via inhibition of NLRP6 inflammasome activation. Our results demonstrated that VD3 substantially represses inflammation and the development of UC in vivo. These findings reveal a new mechanism by which VD3 affects inflammation in UC by regulating the expression of NLRP6 and show the potential clinical use of VD3 in autoimmune syndromes or other NLRP6 inflammasome-driven inflammatory diseases.
- 8 February 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1135930
Open AccessVitamin D3 alleviates inflammation in ulcerative colitis by activating the VDR-NLRP6 signaling pathway
Inflammation is a key factor in the development of ulcerative colitis (UC). 1,25-dihydroxyvitamin D3 (1,25(OH)2D3, VD3), as the major active ingredient of vitamin D and an anti-inflammatory activator, is closely related to the initiation and development of UC, but its regulatory mechanism remains unclear. In this study, we carried out histological and physiological analyses in UC patients and UC mice. RNA sequencing (RNA-seq), assays for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq), chromatin immunoprecipitation (ChIP) assays and protein and mRNA expression were performed to analyze and identify the potential molecular mechanism in UC mice and lipopolysaccharide (LPS)-induced mouse intestinal epithelial cells (MIECs). Moreover, we established nucleotide-binding oligomerization domain (NOD)-like receptor protein nlrp6-/- mice and siRNA-NLRP6 MIECs to further characterize the role of NLRP6 in anti-inflammation of VD3. Our study revealed that VD3 abolished NOD-like receptor protein 6 (NLRP6) inflammasome activation, suppressing NLRP6, apoptosis-associated speck-like protein (ASC) and Caspase-1 levels via the vitamin D receptor (VDR). ChIP and ATAC-seq showed that VDR transcriptionally repressed NLRP6 by binding to vitamin D response elements (VDREs) in the promoter of NLRP6, impairing UC development. Importantly, VD3 had both preventive and therapeutic effects on the UC mouse model via inhibition of NLRP6 inflammasome activation. Our results demonstrated that VD3 substantially represses inflammation and the development of UC in vivo. These findings reveal a new mechanism by which VD3 affects inflammation in UC by regulating the expression of NLRP6 and show the potential clinical use of VD3 in autoimmune syndromes or other NLRP6 inflammasome-driven inflammatory diseases.
- Open Access
- 29 August 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (8) , 1-13
Long noncoding RNA LINC00239 inhibits ferroptosis in colorectal cancer by binding to Keap1 to stabilize Nrf2
Ferroptosis, a novel regulated cell death induced by iron-dependent lipid peroxidation, plays an important role in tumor development and drug resistance. Long noncoding RNAs (lncRNAs) are associated with various types of cancer. However, the precise roles of many lncRNAs in tumorigenesis remain elusive. Here we explored the transcriptomic profiles of lncRNAs in primary CRC tissues and corresponding paired adjacent non-tumor tissues by RNA-seq and found that LINC00239 was significantly overexpressed in colorectal cancer tissues. Abnormally high expression of LINC00239 predicts poorer survival and prognosis in colorectal cancer patients. Concurrently, we elucidated the role of LINC00239 as a tumor-promoting factor in CRC through in vitro functional studies and in vivo tumor xenograft models. Importantly, overexpression of LINC00239 decreased the anti-tumor activity of erastin and RSL3 by inhibiting ferroptosis. Collectively, these data suggest that LINC00239 plays a novel and indispensable role in ferroptosis by nucleotides 1–315 of LINC00239 to interact with the Kelch domain (Nrf2-binding site) of Keap1, inhibiting Nrf2 ubiquitination and increasing Nrf2 protein stability. Considering the recurrence and chemoresistance constitute the leading cause of death in colorectal cancer (CRC), ferroptosis induction may be a promising therapeutic strategy for CRC patients with low LINC00239 expression.
- 29 August 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (8) , 1-13
Open AccessLong noncoding RNA LINC00239 inhibits ferroptosis in colorectal cancer by binding to Keap1 to stabilize Nrf2
Ferroptosis, a novel regulated cell death induced by iron-dependent lipid peroxidation, plays an important role in tumor development and drug resistance. Long noncoding RNAs (lncRNAs) are associated with various types of cancer. However, the precise roles of many lncRNAs in tumorigenesis remain elusive. Here we explored the transcriptomic profiles of lncRNAs in primary CRC tissues and corresponding paired adjacent non-tumor tissues by RNA-seq and found that LINC00239 was significantly overexpressed in colorectal cancer tissues. Abnormally high expression of LINC00239 predicts poorer survival and prognosis in colorectal cancer patients. Concurrently, we elucidated the role of LINC00239 as a tumor-promoting factor in CRC through in vitro functional studies and in vivo tumor xenograft models. Importantly, overexpression of LINC00239 decreased the anti-tumor activity of erastin and RSL3 by inhibiting ferroptosis. Collectively, these data suggest that LINC00239 plays a novel and indispensable role in ferroptosis by nucleotides 1–315 of LINC00239 to interact with the Kelch domain (Nrf2-binding site) of Keap1, inhibiting Nrf2 ubiquitination and increasing Nrf2 protein stability. Considering the recurrence and chemoresistance constitute the leading cause of death in colorectal cancer (CRC), ferroptosis induction may be a promising therapeutic strategy for CRC patients with low LINC00239 expression.
- 15 February 2022
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 79 (2) , 1-17
Sec62 promotes gastric cancer metastasis through mediating UPR-induced autophagy activation
Background and aims Sec62 is a membrane protein of the endoplasmic reticulum that facilitates protein transport. Its role in cancer is increasingly recognised, but remains largely unknown. We investigated the functional role of Sec62 in gastric cancer (GC) and its underlying mechanism. Methods Bioinformatics, tissue microarray, immunohistochemistry (IHC), western blotting (WB), quantitative polymerase chain reaction (qPCR), and immunofluorescence were used to examine the expression of target genes. Transwell, scratch healing assays, and xenograft models were used to evaluate cell migration and invasion. Transmission electron microscopy and mRFP-GFP-LC3 double-labeled adenoviruses were used to monitor autophagy. Co-immunoprecipitation (CO-IP) was performed to evaluate the binding activity between the proteins. Results Sec62 expression was upregulated in GC, and Sec62 upregulation was an independent predictor of poor prognosis. Sec62 overexpression promoted GC cell migration and invasion both in vitro and in vivo. Sec62 promoted migration and invasion by affecting TIMP-1 and MMP2/9 balance. Moreover, Sec62 could activate autophagy by upregulating PERK/ATF4 expression and binding to LC3II with concomitant FIP200/Beclin-1/Atg5 activation. Furthermore, autophagy blockage impaired the promotive effects of Sec62 on GC cell migration and invasion, whereas autophagy activation rescued the inhibitory effect of Sec62 knockdown on GC metastasis. Notably, Sec62 inhibition combined with autophagy blockage exerted a synergetic anti-metastatic effect in vitro and in vivo. Conclusion Sec62 promotes GC metastasis by activating autophagy and subsequently regulating TIMP-1 and MMP2/9 balance. The activation of autophagy by Sec62 may involve the unfolded protein response (UPR)-related PERK/ATF4 pathway and binding of LC3II during UPR recovery involving FIP200/Beclin-1/Atg5 upregulation. Specifically, the dual inhibition of Sec62 and autophagy may provide a promising therapeutic strategy for GC metastasis.
- 15 February 2022
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 79 (2) , 1-17
Sec62 promotes gastric cancer metastasis through mediating UPR-induced autophagy activation
Background and aims Sec62 is a membrane protein of the endoplasmic reticulum that facilitates protein transport. Its role in cancer is increasingly recognised, but remains largely unknown. We investigated the functional role of Sec62 in gastric cancer (GC) and its underlying mechanism. Methods Bioinformatics, tissue microarray, immunohistochemistry (IHC), western blotting (WB), quantitative polymerase chain reaction (qPCR), and immunofluorescence were used to examine the expression of target genes. Transwell, scratch healing assays, and xenograft models were used to evaluate cell migration and invasion. Transmission electron microscopy and mRFP-GFP-LC3 double-labeled adenoviruses were used to monitor autophagy. Co-immunoprecipitation (CO-IP) was performed to evaluate the binding activity between the proteins. Results Sec62 expression was upregulated in GC, and Sec62 upregulation was an independent predictor of poor prognosis. Sec62 overexpression promoted GC cell migration and invasion both in vitro and in vivo. Sec62 promoted migration and invasion by affecting TIMP-1 and MMP2/9 balance. Moreover, Sec62 could activate autophagy by upregulating PERK/ATF4 expression and binding to LC3II with concomitant FIP200/Beclin-1/Atg5 activation. Furthermore, autophagy blockage impaired the promotive effects of Sec62 on GC cell migration and invasion, whereas autophagy activation rescued the inhibitory effect of Sec62 knockdown on GC metastasis. Notably, Sec62 inhibition combined with autophagy blockage exerted a synergetic anti-metastatic effect in vitro and in vivo. Conclusion Sec62 promotes GC metastasis by activating autophagy and subsequently regulating TIMP-1 and MMP2/9 balance. The activation of autophagy by Sec62 may involve the unfolded protein response (UPR)-related PERK/ATF4 pathway and binding of LC3II during UPR recovery involving FIP200/Beclin-1/Atg5 upregulation. Specifically, the dual inhibition of Sec62 and autophagy may provide a promising therapeutic strategy for GC metastasis.
- 13 February 2022
- Published by Wiley in Journal of Digestive Diseases
- Vol. 23 (3) , 183-185
Idiopathic mesenteric phlebosclerosis occurring after long‐term medication with licorice: A case report
- 13 February 2022
- Published by Wiley in Journal of Digestive Diseases
- Vol. 23 (3) , 183-185
Idiopathic mesenteric phlebosclerosis occurring after long‐term medication with licorice: A case report
- Open Access
- 1 November 2021
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (21) , 1619
Patients and physicians’ attitudes change on fecal microbiota transplantation for inflammatory bowel disease over the past 3 years
Background: In the past 3 years, increasing data and experience has become available regarding fecal microbiota transplantation (FMT) for the treatment of inflammatory bowel disease (IBD). However, how this increase in knowledge has impacted the attitudes of patients and physicians is largely unknown. This study aimed to investigate the change of patients’ and physicians’ attitudes towards FMT for IBD treatment. Methods: Questionnaires for patient and physician attitude on FMT for IBD were pilot-tested and developed. Patients and physicians from the same groups completed the questionnaires in 2016 and 2019, separately. The attitudes towards efficacy, adverse events, and methodological features of FMT in 2016 were compared with those in 2019. Results: A total of 1,255 questionnaires from 486 patients and 769 physicians were collected. Over the 3 years, an increased number of patients had heard of FMT and had similarly positive opinions towards using FMT for IBD therapy. Additionally, patients retained the tendency to overestimate the efficacy. The physicians’ perceptions became closer to the findings reported in recent studies in 2019 compared with 2016. However, only a minority of patients and physicians understood the frequency required of FMT courses for induction of clinical remission. In particular, both patients and physicians underestimated the risk of mild adverse events and IBD flare. Conclusions: Patients are receptive towards FMT as therapy for IBD but opportunity remains to improve understanding of benefit and potential risks. Physicians also demonstrated knowledge gaps in use of this therapy. Aligning patient preference and physician knowledge gap will lead to better education and facilitate the development of decision-making guidelines.
- 1 November 2021
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (21) , 1619
Open AccessPatients and physicians’ attitudes change on fecal microbiota transplantation for inflammatory bowel disease over the past 3 years
Background: In the past 3 years, increasing data and experience has become available regarding fecal microbiota transplantation (FMT) for the treatment of inflammatory bowel disease (IBD). However, how this increase in knowledge has impacted the attitudes of patients and physicians is largely unknown. This study aimed to investigate the change of patients’ and physicians’ attitudes towards FMT for IBD treatment. Methods: Questionnaires for patient and physician attitude on FMT for IBD were pilot-tested and developed. Patients and physicians from the same groups completed the questionnaires in 2016 and 2019, separately. The attitudes towards efficacy, adverse events, and methodological features of FMT in 2016 were compared with those in 2019. Results: A total of 1,255 questionnaires from 486 patients and 769 physicians were collected. Over the 3 years, an increased number of patients had heard of FMT and had similarly positive opinions towards using FMT for IBD therapy. Additionally, patients retained the tendency to overestimate the efficacy. The physicians’ perceptions became closer to the findings reported in recent studies in 2019 compared with 2016. However, only a minority of patients and physicians understood the frequency required of FMT courses for induction of clinical remission. In particular, both patients and physicians underestimated the risk of mild adverse events and IBD flare. Conclusions: Patients are receptive towards FMT as therapy for IBD but opportunity remains to improve understanding of benefit and potential risks. Physicians also demonstrated knowledge gaps in use of this therapy. Aligning patient preference and physician knowledge gap will lead to better education and facilitate the development of decision-making guidelines.
- Open Access
Unusual cause of abdominal pain and papule
A 45-year-old man developed multiple papules on the abdomen (with sizes of about 2–15 mm) for 9 months (figure 1), intermittent black stool and abdominal pain for 5 months. Colonoscopy revealed chronic inflammation of the colorectal mucosa (pathological results indicated active inflammation of the mucosa and Epstein-Barr virus positive) (figure 2). CT enterography examinations revealed segmental ileal stenosis in the right lower abdomen. The abdominal pain worsened 3 days before admission. Laboratory examinations during hospitalisation showed that C reactive protein was 31.53 ng/L; fibrinogen was 5.77 g/L and D-dimer was 1308 ng/mL, respectively. On the day of hospitalisation, the patient had sudden aggravation of abdominal pain without flatus and defecation. Physical examination showed abdominal tenderness, rebound pain and muscle tension. Abdominal X-ray indicated intestinal obstruction. Emergency laparotomy was performed. During the operation, a large number of gas, yellow faecal water and abscesses were seen. Multiple ischaemia and perforations in the small intestine (seven places) were detected.
Open AccessUnusual cause of abdominal pain and papule
A 45-year-old man developed multiple papules on the abdomen (with sizes of about 2–15 mm) for 9 months (figure 1), intermittent black stool and abdominal pain for 5 months. Colonoscopy revealed chronic inflammation of the colorectal mucosa (pathological results indicated active inflammation of the mucosa and Epstein-Barr virus positive) (figure 2). CT enterography examinations revealed segmental ileal stenosis in the right lower abdomen. The abdominal pain worsened 3 days before admission. Laboratory examinations during hospitalisation showed that C reactive protein was 31.53 ng/L; fibrinogen was 5.77 g/L and D-dimer was 1308 ng/mL, respectively. On the day of hospitalisation, the patient had sudden aggravation of abdominal pain without flatus and defecation. Physical examination showed abdominal tenderness, rebound pain and muscle tension. Abdominal X-ray indicated intestinal obstruction. Emergency laparotomy was performed. During the operation, a large number of gas, yellow faecal water and abscesses were seen. Multiple ischaemia and perforations in the small intestine (seven places) were detected.